Hexavest’s Vertex Pharmaceuticals VRTX Stock Holding History

Hexavest’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-58	Closed	-$10K	–	490
2019 Q3	$10K	Hold	58	–	–	﹤0.01%	474
2019 Q2	$11K	Buy	+58	New	+$10.1K	﹤0.01%	472

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Hexavest's VRTX Position: Q4 2019 in Review

Hexavest sold out of Vertex Pharmaceuticals (VRTX) in Q4 2019, closing a stake of 58 shares — an estimated $10K sold.

Hexavest first reported a position in VRTX in Q2 2019 and held it in 2 quarters. The position peaked at $11K in Q2 2019. 813 funds tracked by Wall St. Rank hold VRTX as of Q4 2019.

Hexavest reported no remaining Vertex Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Hexavest sold 58 Vertex Pharmaceuticals shares in Q4 2019, an estimated $10K.
Hexavest first reported a position in Vertex Pharmaceuticals in Q2 2019 and held it in 2 quarters.
Hexavest's Vertex Pharmaceuticals position peaked at $11K in Q2 2019.
813 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2019.

Based on Hexavest's 13F filing for Q4 2019, filed 9 Jan 2020.